SnET2-PDT FDA Approval Status

FDA Approved: No
Brand name: SnET2-PDT
Generic name: Tin ethyl etiopurpurin (SnET2) photodynamic therapy (PDT)
Company: Miravant
Treatment for: Macular Degeneration

Development timeline for SnET2-PDT

Date	Article
Jun 1, 2004	Miravant's SnET2 New Drug Application Accepted for Filing by FDA with Priority Review Designation
Mar 31, 2004	Miravant Submits New Drug Application For SnET2-PDT to Treat Macular Degeneration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer